Cancer Microbiome Sequencing Market to Grow with a CAGR of 21.72% through 2030
Growing focus on the
microbiome’s potential in the field of cancers to drive the cancer microbiome
sequencing market in the forecast period, 2026-2030.
According to TechSci Research
report, “Cancer Microbiome Sequencing Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Cancer Microbiome Sequencing Market was valued at USD 514.74 million in 2024 and is expected to reach USD 1674.18 million by 2030 with a CAGR of 21.72% during the forecast period. The decreasing cost of sequencing, growing
occurrences of cancer, and rising investments in microbiome research are the
primary factors driving the demand for the global cancer microbiome sequencing market.
The rising number of patients with cancer, rise in R&D activities, upsurge
in development of novel diagnostic tools based on microbiome for supporting
physicians, increasing healthcare expenditure, and growing awareness of the
use of microbiome sequencing technology are expected to influence the market
demand. Also, the rising adoption of inorganic growth strategies and growth
world population also a key factor for increasing the growth of the cancer
microbiome sequencing market, globally.
However, the lack of high complexity
testing centers in markets, regulatory challenges for direct-to-consumer (DTC)
companies, and existing diagnostic confidence on conventional cancer diagnostics
may hamper the growth of the global cancer microbiome sequencing market.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Cancer Microbiome Sequencing Market"
The global cancer
microbiome sequencing market is segmented into component, technology,
application, end user, regional distribution and company.
Based on Technology, next generation sequencing (NGS) shows the fastest growth in the global cancer microbiome sequencing market, driven by its ability to generate high-throughput, comprehensive, and precise microbial profiles compared to traditional methods like polymerase chain reaction (PCR). NGS enables simultaneous sequencing of millions of DNA fragments, allowing researchers to detect rare, low-abundance microbial species and explore their potential role in cancer development, progression, and treatment response. The accelerated growth of NGS is supported by declining sequencing costs—the cost of sequencing a whole human genome has dropped from nearly USD 100 million in 2001 to less than USD 600 in 2024, according to the U.S. National Human Genome Research Institute (NHGRI)—making it more accessible for academic research, clinical diagnostics, and pharmaceutical R&D. Moreover, NGS provides higher resolution and deeper insights into the cancer-associated microbiome than PCR, which typically focuses on targeted amplification of specific genes and may miss novel or unexpected microbial sequences.
Based on the Region, Asia Pacific shows the fastest growth in the global cancer microbiome sequencing market, driven by rising cancer prevalence, increasing adoption of precision medicine, and growing investments in genomic research across emerging economies. According to the World Health Organization (WHO), Asia accounts for nearly 50% of global cancer cases, with countries such as China, India, and Japan witnessing rapid increases due to lifestyle changes, aging populations, and environmental factors. Governments in the region are actively investing in genomic initiatives— for example, China’s National Key R&D Program allocates significant funding toward microbiome and cancer research, while India’s Genome India Project, supported by the Department of Biotechnology, aims to map the genetic diversity of its population to improve disease prevention and treatment strategies. Technological advancements and the falling costs of next-generation sequencing (NGS) are also enabling wider access to microbiome sequencing services. Many Asia Pacific countries are integrating microbiome research into oncology programs, as understanding the gut and tumor microbiome is increasingly recognized for its potential in improving immunotherapy outcomes. Additionally, partnerships between regional research institutions and global biotech companies are expanding clinical trial activity in the area, with Japan and South Korea emerging as key hubs for microbiome-related cancer trials.
Major
companies operating in Global Cancer Microbiome Sequencing market are:
- Illumina, Inc.
- Eurofins Scientific SE
- QIAGEN NV
- Thermo Fischer Scientific, Inc.
- Oxford Nanopore Technologies plc.
- OraSure Technologies, Inc.
- Pacific Biosciences of California, Inc.
- Psomagen, Inc
- Prescient Medicine Holdings, Inc.
- Micronoma Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“North America region
dominates the market and is expected to maintain its dominance in the
coming years due to the rise in the adoption of highly advanced techniques and
systems. The upsurge in research and development activities, the
presence of market leaders, substantial adoption of high-fidelity cancer
microbiome sequencing products and services for translational research, rising
fund infusions by the federal organizations, and growing cases of cancer in the
region are expected to propel the global cancer microbiome sequencing market
growth till 2030” said Mr. Karan Chechi, Research Director of TechSci
Research, a research based global management consulting firm.
“Cancer Microbiome
Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Component (Kits & Assays, Software,
Services), By Technology (Next Generation Sequencing, Polymerase Chain
Reaction), By Application (Translational Research, Clinical Diagnostics), By
End User (Biotechnology & Pharmaceutical Companies, Academic & Research
Institutions, Hospitals & Clinics, Others), By Region and Competition, 2020-2030F”, has evaluated the future
growth potential of global cancer microbiome sequencing market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global cancer microbiome sequencing market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com